NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

AEON Biopharma, Inc. (AEON) Stock Analysis

AEON Biopharma, Inc. (AEON) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

AEON

$0.24

+$0.01 (+3.76%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AEON with… →

AEON Key Statistics

As of Oct 21, 2026
Trading
Open
$0.24
Previous Close
$0.23
Day's Range
0.24–0.25
52-Week Range
0.18–1.45
Volume
145.43K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.69
Valuation
Market Cap
$11.98M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.39
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$39.22M−193.37%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
49.88M
1-Year Return
−78.74%
Dividend and dates
Avg Volume
7.64M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AEON closed at $0.24, −78.74% over 1 year.

AEON Biopharma, Inc. (AEON) has a market capitalization of $11.98M.

In fiscal 2025, AEON reported revenue of $0.00.

AEON Stock Return by Calendar Year

AEON Biopharma, Inc. (AEON) return since Jan 2023: what $10,000 became

1 year
$10,000 $2,126
−78.74%
3 years
$10,000 $6
−99.94%
Since Jan 2023
$10,000 $3
−99.97%

If you had invested $10,000 in AEON Biopharma, Inc. (AEON) at the close on January 3, 2023, the earliest close on record here, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −87.87% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.16%
2025−97.17%
2024−92.50%
2023−28.43%

As of October 21, 2026.

AEON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$39.22M—
2024$0.00$42.01M—
2022$0.00−$52.56M—
2021$0.00−$55.64M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$16.30M−$39.22M—
2024$0.00—−$27.82M$42.01M—
2022$0.00—−$48.43M−$52.56M—
2021$0.00—−$36.88M−$55.64M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AEON Biopharma, Inc. (AEON) at $11.98M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

AEON last closed at $0.24 on October 21, 2026. That is +$0.01 (+3.76%) against the previous close. Over the past 52 weeks the price has ranged from $0.18 to $1.45. The latest close sits 35.71% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $39.22M. Trailing earnings per share are −4.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2021 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −78.74%. Measured over 3 years, that is −91.66% a year compounded. The reported beta is 0.69. Daily returns over the trailing 3 years annualize to a volatility of 151.71%.

Growth & Income

The record shows no dividend for AEON.

The strongest complete calendar year on file is 2023 at −28.43%; the weakest is 2025 at −97.17%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −78.16% year to date.

Peer Comparison

AEON Biopharma, Inc. (AEON) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AEON Biopharma, Inc. AEON $11.98M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AEON Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Visit website →